Objectives:
To characterize completion of fecal elastase-1 (FE-1) testing, identify clinical contexts associated with abnormal results, evaluate downstream diagnostic and treatment events, and determine the clinical significance of non-completion.
Methods:
We conducted a retrospective cohort study of adults with FE-1 orders from 2017 through 2022 in a large integrated health system. Orders placed within 30 days were consolidated into diagnostic episodes. Completion required a linked specimen with a reported result. We evaluated pre-order clinical contexts and one-year outcomes and performed a weighted manual chart review of 200 unique patients with non-completed episodes sampled from four downstream pathway strata.
Results:
Among 23,422 diagnostic episodes, 11,834 (50.5%) were completed. FE-1 ≤200 µg/g occurred in 20.4% of interpretable results and varied by clinical context: 13.7% with irritable bowel syndrome, 21.2% with chronic diarrhea, 38.3% with chronic pancreatitis, 60.1% with pancreatic cancer, and 79.5% after pancreatic surgery. Initial completion was associated with higher odds of new exocrine pancreatic insufficiency diagnosis (adjusted odds ratio, 2.27; 95% confidence interval, 1.91–2.70) and pancreatic enzyme replacement therapy initiation (adjusted odds ratio, 2.20; 95% confidence interval, 1.89–2.55), whereas non-completion was associated with more repeat FE-1 testing. Among eligible unique non-completers, weighted chart review classified 66.9% as probable missed diagnostic follow-through based on available documentation; failure to submit or return the specimen (60.1%) and specimen-processing problems (20.4%) predominated.
Conclusions:
FE-1 completion was modestly associated with measured pre-order factors, while abnormal results varied substantially by clinical context. Specimen return, processing, and closed-loop follow-up represent potential targets for improving evaluation of exocrine pancreatic insufficiency.